CORT

In the past six months, Corcept Therapeutics' stock price has experienced significant positive movement, gaining approximately 60% since May 31, 2026. This surge was primarily driven by the FDA approval of Lifyorli™ (relacorilant) on March 25, 2026, ahead of its PDUFA date, for platinum-resistant ovarian cancer. Following its launch in April 2026, Lifyorli™ generated $47.6 million in revenue during its first quarter of availability (fiscal Q2 2026), with strong market adoption. Additionally, the company reported exceptional fiscal Q2 2026 financial results on July 29, 2026, exceeding analyst expectations with diluted earnings per share of $0.36 and revenue of $256.1 million, a 32% increase over the same period in 2025. Bolstered by these results, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Between September 16, 2025, and September 15, 2026, the share price increased by 55.38%. Over the past 61 trading days, the stock moved from $73.33 to $113.38, gaining 54.62%, with a period high of $126.38 on August 25, 2026, and a low of $72.62 on June 8, 2026.